Graves Disease Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Prevalence of Hyperthyroidism & Graves’ Disease

The Graves’ disease market continues to expand as incidence climbs in both developed and emerging economies. During the pandemic period, pediatric cases rose 60%^{[1]N Pollack-Schreiber, “Increased incidence of Graves’ disease during the COVID-19 pandemic in children and adolescents in the United States,” Frontiers in Endocrinology, frontiersin.org}, underscoring the role of viral triggers in autoimmune thyroid dysfunction. Higher diagnostic penetration in iodine-replete regions uncovers previously missed subclinical disease, particularly among Asian and White populations with strong genetic predisposition. Pharmaceutical developers leverage these epidemiological insights to refine inclusion criteria, improve trial enrollment, and boost the likelihood of regulatory success. Health systems respond by scaling endocrinology tele-consultation services that lower specialist bottlenecks and enhance early intervention rates. As lifestyle and nutritional transitions continue, incidence growth remains a key demand driver across every tier of care delivery.

Pipeline of Targeted Immunotherapies

Novel FcRn inhibitors and CD40 antagonists reinforce the innovation narrative that positions the Graves’ disease market for sustained premium pricing. Batoclimab posted a 76% response rate in patients uncontrolled on antithyroid drugs, with more than half discontinuing conventional therapy entirely. Clinical differentiation reduces the need for lifelong thyroid replacement and mitigates relapse risk, shifting payer calculus toward disease-modifying solutions. Breakthrough Therapy and orphan drug designations shorten development timelines, encouraging venture investment and licensing deals. As multi-indication platforms emerge, developers exploit scale economies in manufacturing and distribution that further strengthen long-run margins.

Growing Adoption of Radio-Iodine Therapy in High-CV-Risk Patients

Radioactive iodine retains clinical relevance where rapid thyroid ablation lowers atrial fibrillation burden in cardiovascular-risk cohorts. Updated cardiology guidelines support earlier I-131 use, particularly in elderly patients for whom surgery is less feasible. Lithium carbonate co-administration now boosts cure rates by 12%^{[2]Abd-ElGawad "Determining the best dose of lithium carbonate as adjuvant therapy to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis" BMC Endocr Disord, bmcendocrdisord.biomedcentral.com}, improving confidence in remission durability. Personalized dosimetry cuts hospital stays, while remote radiation monitors ease outpatient management. These advances preserve a stable revenue base even as biologics gain popularity, reinforcing multimodal treatment diversity within the broader Graves’ Disease market.

Expanding Reimbursement & Funding for Rare Autoimmune Disorders

Payers steadily broaden coverage criteria for high-cost biologics when evidence shows avoidance of surgery and long-term steroid complications. Aetna now pre-authorizes teprotumumab for adults with thyroid eye disease, creating a benchmark for private insurers. Medicare Advantage plans align by standardizing reimbursement for thyroid surgeries that meet defined necessity thresholds. Manufacturers backfill residual gaps through patient-assistance programs that drive early uptake, generate real-world evidence, and strengthen future reimbursement negotiations. Over the forecast horizon, these policies push the Graves’ disease market toward higher biologic penetration and more predictable revenue streams.

High Total Cost of Lifelong Disease Management

The Graves’ disease market absorbs significant cost pressure when biologic courses exceed USD 380,000, and annual levothyroxine prescriptions top 82 million in the United States. Indirect expenses from monitoring, lost productivity, and comorbidity management add to the burden, especially in low-resource settings where insurance penetration is limited. Currency volatility inflates import costs for active pharmaceutical ingredients, threatening generic supply security. These economic frictions drive value-based-care pilots that link payment to long-term outcomes and stimulate demand for solutions that shorten or eliminate chronic medication use.

I-131 Isotope Supply Chain and Disposal Constraints

Fragile isotope supply constrains radioactive iodine therapy expansion. Aging reactors in Europe and previous shutdowns at Canada’s Chalk River facility expose geographic dependency risks. New American projects require years to come online, while stricter waste-disposal rules raise hospital handling costs. Providers hedge by incorporating thermal ablation or biologic alternatives into treatment algorithms, a trend that redirects share toward less supply-sensitive modalities across the Graves’ disease market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Graves Disease Market Segment Analysis

TSH testing retained 45.92% revenue share in 2025, underscoring its status as the primary screening and monitoring tool. Nevertheless, antibody assays are expanding at a 6.15% CAGR as clinicians correlate thyroid-stimulating immunoglobulin (TSI) titers with disease activity and treatment response. The Graves’ disease market accommodates both modalities, yet rapid-turnaround antibody panels increasingly guide personalized treatment strategies. Free T4 and T3 measurements remain indispensable for dose titration, while thyroglobulin tests monitor post-surgical recurrence. Vitamin D status testing is gaining ground after studies linked serum levels of 20-29 ng/mL to better TRAb remission rates.

A growing installed base of point-of-care platforms moves initial diagnostics closer to primary care, accelerating specialist referrals and expanding the overall Graves’ Disease market. High-resolution ultrasound and fusion imaging add structural insights that drive selection between radioiodine, surgery, or emerging ablation techniques. The Graves’ disease industry benefits from bundled diagnostic-and-therapy offerings that streamline patient journeys and raise provider margins. As reimbursement policies catch up with the clinical value of antibody profiling, labs capable of multiplex testing are poised to capture additional share.

Anti-thyroid drugs still control 40.78% revenue in 2025, reflecting easy oral dosing and low acquisition cost. Yet FcRn inhibitors and IGF-1R antagonists are set to generate the fastest 6.02% CAGR through 2031, rewriting the value hierarchy of the Graves’ disease market. Batoclimab’s 76% response rate in refractory patients illustrates the step-change in efficacy. Radioactive iodine therapy persists, favored for elderly cardiovascular-risk cohorts, while supply uncertainty limits aggressive expansion plans.

Thermal ablation offers a minimally invasive bridge option, achieving 96% one-year euthyroid status with minimal complications. Surgical thyroidectomy remains the definitive approach for large goiters, malignancy suspicion, or treatment failure, with updated nerve-monitoring protocols reducing complication rates. Overall, diversified modality availability protects patient choice, though the revenue mix skews increasingly toward biologics as payers embrace long-term cost avoidance.

Adults aged 18-64 accounted for 62.12% of the Graves’ disease market share in 2025, reflecting peak disease onset years. This cohort benefits from the broadest trial access and drives data generation that shapes global guidelines. Pediatric cases, growing at 6.21% CAGR, introduce distinct needs around growth, development, and medication adherence. Lower remission rates and higher symptom severity push clinicians to explore immunotherapies and tailored dosing regimens for children . Neonatal thyrotoxicosis cases underscore the need for maternal antibody screening, influencing obstetric protocols.

Geriatric patients often favor radioiodine due to comorbidity concerns, while novel biologics may reduce polypharmacy and improve quality of life. The Graves’ disease market therefore spans three age-defined sub-segments, each requiring unique safety data, formulation options, and support programs. Such complexity fuels investment in age-stratified research and opens secondary opportunities in caregiver support services.

Hospitals captured 51.76% of the Graves’ disease market size in 2025 through integrated diagnostic, surgical, and nuclear medicine capabilities. Multidisciplinary endocrinology boards improve complex-case outcomes and facilitate early enrollment in investigational biologic trials. Specialty clinics leverage telemedicine to maintain frequent contact during dose titration, improving adherence and capturing ancillary lab revenues. Online and retail pharmacies, expanding at 6.44% CAGR, benefit from the oral formulation trend and direct-to-consumer prescription fulfillment models.

Ambulatory surgical centers gain traction for outpatient thermal ablation and minimally invasive thyroidectomy, offering lower overhead and faster scheduling. Digital consultation platforms such as Medii link primary-care physicians to specialists, accelerating referral cycles and raising diagnostic throughput. As therapy delivery decentralizes, manufacturers craft omnichannel distribution strategies to safeguard patient experience and ensure temperature-controlled biologic integrity. The Graves’ disease industry thus illustrates how virtual care and retail pharmacy growth can coexist with traditional hospital dominance.

Geography Analysis

North America Graves Disease Market

North America maintains leadership with 39.42% revenue share in 2025, supported by advanced infrastructure, deep clinical-trial networks, and payer readiness to cover first-in-class biologics. The region’s 4.38% CAGR through 2031 stems from steady transition to value-based care and widening access to precision diagnostics. United States providers increasingly bundle imaging, antibody panels, and endocrine consultations into integrated care pathways, reducing time to treatment initiation. High private-equity investment in specialty clinics further accelerates patient throughput and data generation for real-world evidence studies.

APAC, EMEA and South America Graves Disease Market

Asia Pacific is the fastest-growing arena for the Graves’ disease market, rising at 5.98% CAGR. Government health-insurance expansions in China and India drive higher diagnostic uptake, while Japan pioneers outpatient ablation protocols that shorten wait times and lower total cost of care. Domestic biotech investment unlocks localized manufacturing for biosimilar antibodies, boosting affordability. Telemedicine adoption soars in rural provinces, enabling specialists to manage complex cases remotely. Overall, demographic scale, economic growth, and policy reform combine to make Asia Pacific the primary engine of incremental revenue. Europe contributes a balanced 4.59% CAGR, anchored by public healthcare systems that emphasize cost-effectiveness and early technology assessment. Harmonized regulatory frameworks streamline biologic approvals, while well-established thyroid research consortia facilitate multicenter trials. Middle East & Africa achieves a 5.61% CAGR as infrastructure upgrades and rising chronic-disease awareness improve specialist access. Regional centers of excellence in the Gulf export know-how across North Africa, while pharmaceutical manufacturers target tender contracts to secure formulary placements. South America advances at 5.05% CAGR, with Brazil’s universal health system adding antibody testing reimbursement and Argentina incentivizing domestic levothyroxine production to cut import dependence. Collectively, these developments widen the global footprint of the Graves’ disease market and encourage multinational players to localize both manufacturing and medical education programs.

Regulatory Landscape

Graves disease regulation spans established endocrine care standards and product-specific approvals that increasingly center on targeted immunology and high-cost biologics, alongside longstanding controls for antithyroid drugs, surgery, and radioactive iodine (including radiation-safety and medical-waste handling requirements at treating facilities). In June 2026, the US FDA approved Viridian Therapeutics' Lumvoa (veligrotug-vvze) for thyroid eye disease (TED) across both active and chronic disease, reinforcing an IGF-1R class pathway tied to Graves-associated complications and tightening payer and formulary scrutiny around labeled populations and treatment duration.

In Europe, the EMA and the European Commission expanded the targeted-biologic footprint for TED in 2025 through EU-wide marketing authorization for Tepezza (teprotumumab). This provided an additional benchmark for benefit-risk expectations, pharmacovigilance, and real-world data generation in autoimmune thyroid-related disease. Separately, guideline bodies shape standard-of-care and clinical trial design, including the American Thyroid Association publishing updated 2026 guidance for thyroid disease in preconception, pregnancy, and postpartum, which affects therapeutic choices and monitoring pathways for Graves disease in these subpopulations.

Value Chain Analysis

The Graves disease value chain begins with patient presentation in primary care, OB-GYN, ophthalmology, and endocrinology settings, followed by laboratory diagnostics (TSH, free T4/T3, and TRAb/TSI antibody assays) and imaging (ultrasound and advanced thyroid imaging where available). Treatment selection then drives downstream services, including generic antithyroid drug dispensing through retail and online pharmacies, hospital-based nuclear medicine workflows for I-131 administration, and operating-room and device supply for thyroidectomy and thermal ablation. For biologics used in Graves-associated thyroid eye disease, the chain also depends on specialty distribution plus cold-chain logistics.

The innovation-led portion of the chain is increasingly defined by clinical development and manufacturing scale-up for complex biologics and novel modalities, with global trial execution and specialty-channel distribution as critical handoffs. Pipeline activity across multiple sponsors reflects this shift, including Immunovant initiating a global Phase 2b study of IMVT-1402 in 2025, Sanofi initiating a Phase 2 trial of rilzabrutinib in 2025, and argenx moving into Phase 3 evaluation of subcutaneous efgartigimod in 2026. These programs increase the importance of CDMO capacity, device and combination-product readiness for subcutaneous delivery formats, and specialty pharmacy services that support adherence, benefits verification, and patient support in higher-acuity autoimmune care.

Market Opportunities and Future Outlook

A central whitespace in Graves disease management is durable disease modification that reduces relapse and long-term medication burden versus symptom control with antithyroid drugs, radioactive iodine, and surgery. The 2026 FDA approval of Viridian Therapeutics' Lumvoa (veligrotug-vvze) for thyroid eye disease across both active and chronic disease broadens access to targeted IGF-1R antagonism within Graves-associated complications. That creates a clearer commercial and clinical pathway for companies building adjacent autoimmune thyroid portfolios and companion services such as specialty pharmacy support, infusion-to-subcutaneous transitions, and outcomes tracking.

Another opportunity is expanding targeted immunology directly in Graves disease beyond orbitopathy, supported by late-stage and mid-stage trial activity that adds optionality across mechanisms and routes of administration. In June 2026, Biohaven initiated a pivotal Phase 3 program for BHV-1300 in Graves disease, and argenx initiated Phase 3 evaluation of subcutaneous efgartigimod in adult Graves disease. Together, these developments point to more scalable, outpatient-friendly biologic delivery. They also create room for diagnostics and care-pathway optimization, including broader TRAb/TSI testing adoption to select patients for targeted approaches and standardize monitoring across hospital and specialty clinic networks.